10-20-16: Dr. Vincent Cryns, MD, Professor and Trainer in the MCP Program, and his research team have developed a new strategy to treat triple-negative breast cancer by metabolically priming cancer cells to respond to a targeted cancer therapy. The new clinical trial involves a low-methionine diet in combination with a new cancer drug that actives cell death. It’s based on research from the laboratory of Dr. Vincent Cryns, head of the Division of Endocrinology, Diabetes and Metabolism in the Department of Medicine, and the trial will be led by Dr. Ruth O’Regan, head of the Division of Hematology and Medical Oncology in the Department of Medicine. For more information about the research leading to this study, see http://www.medicine.wisc.edu/…/research-suggests-new-approa… and http://www.med.wisc.edu/…/clinical-trials-test-dietar…/49457